IP Library Granted Patent US 9,920,027
Granted Patent B2
US 9,920,027 · App. 14/874,318 · Granted Mar 20, 2018

4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same

Inventors: Alexander L. Ruchelman (Cream Ridge, NJ); George W. Muller (Rancho Santa Fe, CA); Hon-Wah Man (Princeton, NJ); Roger Shen-Chu Chen (Edison, NJ)
Assignee: Celgene Corporation
C07D401/04A61K31/454A61K31/4709A61K38/00A61K39/0011A61K45/06C07D401/14C07D405/14C07D409/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,027
App. No.
14/874,318
Granted
Mar 20, 2018
Kind
B2
Abstract

Provided are 4′-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

Claims (9)

1. A compound of formula:

or a pharmaceutically acceptable salt, solvate, prodrug, clathrate, or stereoisomer thereof, wherein:

Y is C═O or CH 2 ; and

R 1 is alkenyl, alkynyl, bicyclic aryl, cycloalkyl, cycloalkylalkyl, arylaminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, or cycloalkylcarbonyl; and wherein R 1 is optionally substituted with one or more groups selected from alkoxy, halo, alkyl, carboxy, alkylaminocarbonyl, alkoxycarbonyl, nitro, amine, nitrile, haloalkyl, hydroxy, and alkyl sulfonyl.

2. The compound of claim 1 , selected from:

3. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

4. A compound having the formula:

or a pharmaceutically acceptable salt, solvate, prodrug, clathrate, or stereoisomer thereof.

5. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2017
From: CHEN, ROGER SHEN-CHU
To: CELGENE CORPORATION
Reel/Frame 044425/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2016
From: RUCHELMAN, ALEXANDER L.; MULLER, GEORGE W.; MAN, HON-WAH
To: CELGENE CORPORATION
Reel/Frame 038082/0852 →
Continuity (5)
Continuation 14083205 · Nov 18, 2013
Division 13410216 · Mar 1, 2012
Continuation 12077715 · Mar 19, 2008
Provisional Application 60919323 · Mar 20, 2007
Related Publication 20160024048A1 · Jan 28, 2016